Navigation Links
TOMA Biosciences Releases the COMPASS Tumor Profiling System
Date:3/30/2017

American Association for Cancer Research (AACR) Annual Meeting 2017

TOMA Biosciences launches the COMPASS Tumor Profiling System™ - a simple and efficient workflow pathway from tumor, library preparation, sequencing, data analysis, clinical annotation, through reporting. Now, clinical researchers have everything they need to find clinically meaningful changes in tumor DNA.

The core of the COMPASS Tumor Profiling System is the Oligo Selective Sequencing capture assay, TOMA OS-Seq™, a patented technology invented at Stanford University. TOMA OS-Seq delivers unparalleled uniform sequence data of cancer genes from damaged DNA present in FFPE tumor specimens. The core offering of COMPASS allows the capture of tumor DNA from 130 cancer genes and can be customized to any genes of interest.

The COMPASS Tumor Profiling System includes:

  • a comprehensive set of DNA library preparation reagents
  • reference materials to assess sensitivity and specificity for validation
  • proprietary sequence data analysis software for somatic variant identification
  • options for annotation and reporting

COMPASS data analysis is performed through TOMA Stratus™. Stratus is a simple to use, cloud-based service with a web interface to easily upload data and download results. Within Stratus, COMPASS Analysis uses a proprietary method constructed to identify changes specific to the tumor DNA and removes inherited changes that many laboratories report without a specific somatic link.

COMPASS is a complete solution for clinical researchers looking to implement cancer genomics with superior performance while reducing cost and complexity.

“Our team set out to build a simple and complete solution for clinical researchers to analyze tumor DNA and produce actionable findings; with COMPASS they have achieved that aim.” said Wolfgang Daum, TOMA President and CEO.

“Finally, clinical researchers have what they need to simplify operations, improve accuracy and reduce costs. COMPASS can be implemented by clinical researchers and validation-ready in under a week.” commented Dr. Daum.

In addition to the core offering which includes the reagents, reference materials, and secondary analysis software, COMPASS enables several downstream interpretation options for clinical researchers, including access to curated clinical annotation information and reporting tools.

"FOR RESEARCH USE ONLY"

To learn more: attend ‘From Tumor to Action’ webinar.

About TOMA Biosciences
TOMA Biosciences Inc. is a genomics information company and the developer of the COMPASS Tumor Profiling System. COMPASS makes cancer genomics simple. The system includes everything a clinical laboratory needs to detect genomic changes in tumors including many missed by other methods. With its core sequencing technology invented at Stanford University, TOMA Biosciences provides a comprehensive solution to prepare tumor DNA for sequencing and reveal somatic variants. The company is led by innovative scientists, clinicians and technology developers to enable clinical laboratories, hospital systems and research institutions around the world to do cancer genomics. Headquartered in Foster City California, TOMA Biosciences is a commercial stage, private venture-backed company.

Read the full story at http://www.prweb.com/releases/2017/03/prweb14194517.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
2. Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit
3. Avelas Biosciences Appoints Alexey Vinogradov, Ph.D., to Board of Directors
4. Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotor Pathology
5. DuPont Industrial Biosciences Leader Presents Major Advances in Biomaterials at 2017 Advanced Bioeconomy Leadership Conference
6. Luxcel Biosciences and HD Biosciences Enter Collaboration Agreement for Mitochondria Toxicity & Metabolism Assays for Preclinical Drug Safety Evaluation
7. ACEA Biosciences Hires Roger Luo as Vice President of Global Clinical Development
8. Research Reports Coverage on Biotech Stocks -- Anthera Pharma, Arrowhead Pharma, Pacific Biosciences of California, and Conatus Pharma
9. Fluxion Biosciences Appoints Genetracer Biotech of Spain As an Isoflux Liquid Biopsy Certified Service Provider
10. Vortex Biosciences Announces Commercial Launch of Fully Automated System for CTC Isolation
11. Caprion Biosciences wird Kurzlehrgang und Poster bei Molecular Medicine Tri-Conference in San Francisco präsentieren
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Village, CA (PRWEB) , ... August 17, 2017 ... ... technology for cancer research and personalized medicine, today announced the launch of a ... Kansas City, Missouri. The study’s goal is to evaluate the potential for early ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... different cell type. Many treatments for specific cancers, such as breast, prostate, or ... treatment is androgen deprivation therapy for advanced prostate cancer. , This therapy ...
(Date:8/16/2017)... ... August 16, 2017 , ... We are proud to announce ... at our Dilworth, MN site. The inspection took place Monday, July 31st through ... part of a routine Bioresearch Monitoring Program (BIMO) with the USFDA wherein multiple ...
(Date:8/15/2017)... STANFORD, Calif. , Aug. 15, 2017 After spending ... resources and support with crowdsourced data collection, GeneFo now offers this ... interested in aligning and amplifying support, adherence, and data collection vis ... with medical foundations mark the successful launch of this offer. ... GeneFo ...
Breaking Biology Technology:
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
Breaking Biology News(10 mins):